Author:
Day F L,Leong T,Ngan S,Thomas R,Jefford M,Zalcberg J R,Rischin D,McKendick J,Milner A D,Di Iulio J,Matera A,Michael M
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 15: 277–284
2. Chun HG, Puccio CA, Mittelman A (2001) Weekly docetaxel and continuous infusion (CI) 5-fluorouracil (5-FU) in elderly patients (Pts) with cancer of the stomach and distal esophagus. Proc Am Soc Clin Oncol 20: 2001 (abstract 645)
3. Einzig AI, Neuberg D, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA, Benson III AB (1996) Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87–93
4. Font A, Arellano A, Fernández-Llamazares J, Casas D, Boix J, Cardenal J, Margeli M, Manzano JL, Abad A, Rosell R (2007) Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clin Trans Oncol 9: 177–182
5. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226–234